3B BlackBio Dx Ltd reported a strong FY26, with consolidated profit rising 26% to Rs 59.93 crore and revenue climbing 47% to Rs 141.92 crore. Growth was primarily driven by its diagnostics segment and the successful integration of Belgium-based Coris BioConcept. The company also announced a final dividend of Rs 5 per share for the fiscal year.
3B BlackBio Dx Reports FY26 Profit of Rs 59.93 Crore
Revenue grew 47% to Rs 141.92 crore, while PAT rose 26% to Rs 59.93 crore.
Reader Takeaway: Strong diagnostics growth and international expansion offset agrochemical softness; monitor upcoming IVDR regulatory compliance and global costs.
What just happened
3B BlackBio Dx Ltd released its consolidated financial results for FY 2025-26, showing significant top-line and bottom-line growth. The diagnostics segment, fueled by the TRUPCR portfolio, remains the company’s primary engine, contributing Rs 131.12 crore in revenue—a 56% year-on-year increase. The company's EPS rose to Rs 69.94, compared to Rs 55.66 in the previous year.
Why this matters
The successful integration of the Belgium-based Coris BioConcept has transformed the company’s product offering, allowing for a broader range of rapid diagnostics alongside traditional PCR solutions. International growth was also a key highlight, with the UK subsidiary, TRUPCR Europe Limited, recording a 36% rise in sales. These results demonstrate the firm's ability to scale its molecular diagnostics leadership beyond domestic borders.
Business and Operations
The company's diagnostic footprint now spans over 70 countries, with new market entries in the APAC and African regions. Conversely, the smaller agrochemicals division faced headwinds, reporting revenue of Rs 10.80 crore compared to Rs 12.19 crore, impacted by erratic monsoon patterns and sectoral demand fluctuations. However, the division remains both profitable and debt-free.
Corporate Action
The Board has recommended a final dividend of Rs 5 per share (50% of face value). The record date for the payout is September 22, 2026, with shareholder approval sought at the upcoming 54th Annual General Meeting on September 29, 2026. Payments are expected to be disbursed on or after October 5, 2026.
Risks to watch
Management has identified several risks, including geopolitical volatility, potential supply chain disruptions, and pricing pressures from low-cost competitors. Crucially, the company is actively working toward IVDR certification for Class C products to ensure uninterrupted access to European markets, a process that carries inherent regulatory timelines.
What to track next
Investors should monitor the impact of ongoing R&D investments, specifically the commercialization of new Digital PCR assays, and the progress of the company’s regulatory applications in the European Union.